Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?
- 3.6k Downloads
Parkinson’s disease patients exhibit progressive spreading of aggregated α-synuclein in the nervous system. This slow process follows a specific pattern in an inflamed tissue environment. Recent research suggests that prion-like mechanisms contribute to the propagation of α-synuclein pathology. Little is known about factors that might affect the prion-like behavior of misfolded α-synuclein. In this review, we suggest that neuroinflammation plays an important role. We discuss causes of inflammation in the olfactory bulb and gastrointestinal tract and how this may promote the initial misfolding and aggregation of α-synuclein, which might set in motion events that lead to Parkinson's disease neuropathology. We propose that neuroinflammation promotes the prion-like behavior of α-synuclein and that novel anti-inflammatory therapies targeting this mechanism could slow disease progression.
Keywordsα-Synuclein Neuroinflammation Prion-like Parkinson's disease Synucleinopathies Dual-hit hypothesis Proteinopathy
Age-related neurodegenerative disorders, including Parkinson’s disease (PD), are neuropathologically characterized by accumulation of misfolded proteins and the loss of neurons along with sustained neuroinflammation. Clinically, PD patients experience both motor (e.g., bradykinesia, resting tremor, rigidity, and postural instability) and non-motor symptoms (e.g., hyposmia, constipation, sleep disturbances, depression, and dementia). Age is considered the single greatest risk factor for developing PD with 4–5 % of people over 85 years developing the disease . In PD, dopamine-producing neurons in the substantia nigra pars compacta (SNpc) die and there is a concomitant decrease of dopaminergic innervation in the striatum. Furthermore, alpha-synuclein (α-syn) misfolds and forms intraneuronal aggregates in several brain regions. α-Syn is a 140-amino acid protein encoded by a single gene located in chromosome 4  and was first described to be present in the nucleus and presynaptic terminals of normal neurons . In PD and the related synucleinopathies multiple system atrophy and dementia with Lewy bodies, misfolded and aggregated α-syn forms intra-cytoplasmic inclusions. In PD, they are located in neurons and are called Lewy bodies (LB) and Lewy neurites (LN) [4, 5, 6]. The idea that α-syn plays a central role in PD pathogenesis is supported by the link between three missense α-syn mutations, i.e., Ala53Thr , Ala30Pro , and Glu46Lys  and autosomal dominant early-onset PD. Furthermore, multiplications of the gene cause familial forms of neurodegenerative disease with parkinsonian features  and certain SNPs in the α-syn promoter are associated with increased risk for PD . Recent studies suggest that prion-like cell-to-cell transfer of possibly misfolded α-syn contributes to the spreading of neuropathology from one brain region to the next [12, 13, 14, 15, 16, 17].
Although there is no consensus on the causes of sporadic PD, neuroinflammation appears to play an important role (reviewed in ). Several questions still remain: how, if at all, is neuroinflammation linked to α-syn misfolding and aggregation? For example, does neuroinflammation trigger α-syn misfolding or does aggregated α-syn cause microglia activation and neuroinflammation? Furthermore, does neuroinflammation promote cell-to-cell transfer of α-syn and seeding and development of new α-syn aggregates? Alternatively, does the inflammatory process delay the prion-like spread of α-syn? In this review, we will discuss various aspects that drive pathological alterations of α-syn with a special focus on how neuroinflammation might affect the different steps.
Involvement of Immune Pathways in the Brain of Patients with Parkinson’s Disease
Inflammation is a specialized reaction of the body to harmful agents or insults to tissue. Inflammatory processes in the nervous system are called "neuroinflammation" and they are characteristic to most neurodegenerative diseases, including PD. Classically, inflammation and neuroinflammation involve innate and adaptive immune responses that are regulated by secreted factors (e.g., cytokines, chemokines, complement proteins, acute phase proteins, reactive oxygen species (ROS), and arachidonate metabolites; reviewed in [19, 20]). Interestingly, genetic alterations in several immune function-related genes (e.g., DJ-1, leucine-rich repeat protein kinase-2 (LRRK2) and HLA-DR) can cause familial PD or increase the risk of developing PD (all studies and meta-analyses collected in www.pdgene.org). This points to a key role for immune pathways in the pathogenetic mechanisms of PD which are possibly triggered by aging, oxidative stress, or abnormal forms of α-syn (reviewed in ).
Microglia and astrocytes are resident immune cells of the brain. The expression of specific markers associated with these cells (typically Iba-1, CD11b, and MHC class II for microglia, GFAP for astrocytes) increases with severity of neuroinflammation. Positron emission tomography imaging studies employing microglia-specific markers point to an early involvement and cerebral propagation of neuroinflammation in PD [22, 23]. Histological analysis of the substantia nigra in PD patients shows activated microglia [24, 25, 26], a high density of astrocytes , and in some cases also infiltrating T lymphocytes [26, 28]. Furthermore, postmortem PD brains exhibit increased levels of tumor necrosis factor (TNF)  and interleukin (IL)-1 and IL-6 . The cerebrospinal fluid (CSF) of PD patients differs from that collected from Alzheimer’s disease (AD) patients, other neurodegenerative disorders or healthy individuals . The CSF levels of transforming growth factor β1 and 2 (TGFβ1 and TGFβ2)  and ratios between amyloid-β (Aβ) 42 with fractalkine/CX3CL1 , as well as levels of complement factors C3 and fH , are all altered in PD. Whether the clinical findings should be taken as evidence that neuroinflammation directly contributes to neurodegeneration in PD is not clear. The secreted factors and activated immune cells are not just potentially neurotoxic, but can also exert neuroprotective effects in neurodegenerative disorders (reviewed in [35, 36]).
In summary, signs of neuroinflammation and genetic links between PD and immune function point to a possible role of immune pathways in PD. Whether inflammation is beneficial or detrimental in this context remains unclear and we think it is pertinent to ask the question what role inflammation could specifically play in propagation of synucleinopathy in PD.
Recent Updates About the Link Between α-Synuclein Aggregation and the Effect of Inflammation
It has been hypothesized that inflammation triggers, or at least contributes to, the development of α-syn pathology . Indeed, in cellular assays, misfolded α-syn species can trigger activation of microglia [37, 38, 39, 40, 41, 42], one of the hallmarks of the neuroinflammatory process. Although a specific receptor for α-syn binding to microglia is still unknown, these cells can take up extracellular α-syn [43, 44] that in turn triggers the release of soluble immune modulators. The vulnerability of dopaminergic neurons to inflammation has also been linked to α-syn, as genetic ablation of α-syn in animal models decreases the sensitivity of these cells to inflammatory challenges . Factors released from activated microglia can further enhance oxidative stress, protein misfolding, and aggregation, creating a positive feedback loop promoting degeneration of dopaminergic cells [46, 47]. Together, it remains unclear whether α-syn aggregation is a cause or consequence of inflammation.
Approximately 90 % of α-syn found in LBs is constitutively phosphorylated at serine 87 (S87-P) and serine 129 (S129-P). By contrast, less than 5 % of α-syn is phosphorylated at serine 129 in healthy human brain [48, 49, 50]. Phosphorylation of α-syn in neuronal cell lines has been linked to detrimental activation of microglia in mixed cell culture systems , but whether phosphorylation of α-syn induces inflammation or vice versa is not fully understood. Furthermore, the precise roles of phosphorylation or other post-translational modifications of α-syn for neurotoxicity, formation of aggregates, and activation of microglia are not clear, with different studies reporting conflicting results [52, 53, 54, 55].
Nitrated forms of α-syn have previously been suggested to be crucial to the pathogenesis of synucleinopathies  and nitrated α-syn can trigger inflammation and microglia activation [57, 58]. One study has shown that nitrated α-syn may be able to recruit peripheral leukocytes in cervical lymph nodes in a toxin-based (systemic injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, (MPTP)) mouse model of PD. The same study also shows that adoptive transfer of T cells from syngeneic mice immunized with nitrated α-syn worsens dopaminergic neuron loss after MPTP treatment of recipient mice . This indicates that certain adaptive immune mechanisms could play a role in PD pathobiology.
A recent study suggests that α-syn may be modified by inflammation caused by expression of human wild-type or mutant P301L Tau . Both forms of Tau cause microglial changes and increase IL-6 and TNF-α levels while also increasing the levels of endogenous α-syn and S129-P α-syn.
Inflammation and aggregation of α-syn are dynamically interlinked and this interaction probably plays a key role in the pathogenesis of PD. As discussed in this review, there is increasing evidence that α-syn aggregation may be initiated by a seeding mechanism that could spread throughout neurons in a prion-like fashion possibly involving other amyloidogenic proteins. For example, fragments of α-syn are commonly found in Aβ plaques in the brain of AD patients , and certain rare mutations leading to familial forms of AD have been associated with LB pathology as well [61, 62]. Aggregation of α-syn and Aβ can trigger neuroinflammation, e.g., it activates microglia (for reviews see [63, 64]). Oxidative stress produced by neuroinflammation is reported to be a cellular consequence of α-syn aggregation, and excessive levels of free ROS can trigger more inflammation and α-syn aggregation [65, 66, 67]. This vicious feed-forward loop of aggregation-induced neuroinflammation that in turn causes more aggregation may be a central mechanism in the pathogenesis of PD and other proteinopathies of the brain.
The NAD-dependent deacetylase, sirtuin 1 (SIRT1), has been recently identified as a possible regulator of α-syn aggregation. Sirtuins are known to have anti-aging effects in nematodes and it is suggested that this family of enzymes may also play an important role in the regulation of inflammation (reviewed in depth by Galli et al. ). Recently, it was demonstrated that overexpression of SIRT1 in A53T α-syn transgenic mice increases their lifespan and reduces α-syn aggregation, and conversely, knocking-out SIRT1 has the opposite effect . The underlying mechanism has been suggested to be lack of SIRT1-regulated activation of molecular chaperons, which leads to aggregation of α-syn. Thus, sirtuins affect both α-syn aggregation and inflammation and could provide a molecular link between these two processes in PD.
The development and maintenance of dopaminergic neurons is regulated by the orphan receptor Nurr1 . In addition to its role in neurons, loss of Nurr1 also disinhibits the NF-kB signaling cascade in astrocytes and microglia leading to increased secretion of neurotoxic mediators by these cells thereby promoting the loss of dopaminergic neurons in a mouse model of PD . Rare mutations in Nurr1 have been associated with a late-onset familial form of PD, which presents with reduced expression of Nurr1 in somatic cells including peripheral immune cells . This link between Nurr1, inflammation, and PD phenotype is intriguing, but it remains to be shown whether it is relevant to α-syn aggregation.
Spread of Synucleinopathy and Progression of Parkinson’s Disease
The extent of α-syn pathology in the brain is believed to correlate to neurological disease stage . Thus, just as the progression of symptoms tends to follow a predictable pattern, e.g., with certain non-motor symptoms preceding the onset of motor dysfunction, the progression of neuropathological changes are believed to follow a highly replicable pattern. Postulated by Braak and colleagues, this progression is divided into six stages in PD, starting first with the simultaneous appearance of α-syn aggregates in anterior olfactory structures and the vagal nerve. Thereafter, the pathology spreads rostrally, indicated by LNs and to some extent LBs. During stage 2, the pathology manifests itself in the caudal raphe nucleus, in the gigantocellular reticular nucleus, and in the coeruleus–subcoeruleus complex. It is not until stage 3 where it appears in the substantia nigra. At stage 4, lesions are detected in proencephalic regions and finally reach areas of neocortex and prefrontal cortex at the last stages . This progressive pattern of appearance of α-syn aggregates in the brain suggests two possible routes for the spread of synucleinopathy into the brain following long and unmyelinated axonal projections, with a retrograde or anterograde progression : first, the gastrointestinal route from the enteric nervous system (ENS) to the central nervous system (CNS) via dorsal motor neurons of the vagus (DMV) and the intermediolateral nucleus of the spinal cord [76, 77, 78]; and second, the olfactory route, from the olfactory bulb to the midbrain via other olfactory areas and the limbic system .
Several groups have debated the validity of the notion of progression of synucleinopathy and report a broad range of roughly 50–80 % of cases concurring with Braak’s staging [80, 81, 82] or concluding that it can be readily applied to most subjects . In addition, other clinical studies on metabolic, structural, and functional data revealed that neuronal populations are differentially vulnerable to α-syn pathology and hence dysfunction is not in accordance to the proposed staging system . Despite the controversy about the interpretation of neuropathology linked to clinical symptoms, these [80, 81, 82] and other studies [85, 86, 87] have led to the proposal of a unified staging system for all Lewy body disorders .
Interestingly, an estimated proportion of 90 % of PD patients exhibit olfactory deficits [89, 90, 91]. Several studies detected olfactory deficits early in the course of the disease, before the appearance of motor symptoms (for review, see ). Olfactory disturbances occur both in familial and sporadic forms of PD . Histological studies in PD have also revealed a high degree of degeneration of olfactory cells, especially in the anterior olfactory nucleus (AON), which has been correlated to disease duration and LB load in the AON and olfactory bulb (OB) . Thus, it has been proposed that PD might be primarily a disorder of olfaction  and that the olfactory pathways should be of high interest to study early PD stages.
Other histological studies in pre-symptomatic subjects, who go on to develop PD later in life, or PD patients with colonic bacterial infection, demonstrate pathological changes in the ENS that are associated with premotor symptoms involving the gastrointestinal (GI) tract and aggregation of α-syn in the ENS [94, 95, 96, 97]. Indeed, the majority of PD patients display accumulation of pathology-related phosphorylated α-syn in enteric neurons . In line with these findings, the DMV connecting the ENS to the CNS has long been known to be severely affected in PD, potentially influencing GI functions . GI-related non-motor symptoms therefore might represent a prodromal stage of PD.
Together, these data suggest that olfactory and enteric regions might be the starting points of the disease that spreads then to the CNS. Based on this idea, Hawkes et al. proposed a dual-hit hypothesis: a neurotropic pathogen could attack the nervous system from two routes—anterogradely through olfactory tracts and retrogradely through the vagal nerve—and this pathogen could enter the brain through the olfactory and enteric epithelium [79, 99]. Apart from targeting neurons directly, it is quite possible that a pathogen triggers local inflammatory processes, which could initiate synucleinopathy in olfactory and enteric regions leading to a progression of pathology. In the following sections, we describe how inflammation in the olfactory system and in the GI tract might be triggers that start the process of α-syn aggregation.
A Possible Role for Neuroinflammation in the Olfactory Bulb as a Trigger for PD
According to histological studies of PD patients' brains, α-syn abnormalities observed in anterior olfactory structures at Braak’s stage 1 are restricted to the AON and OB [74, 100]. More recent studies have demonstrated that after this step, the pathology spreads slowly into other olfactory regions like the piriform, periamygdaloid and entorhinal cortices, and the olfactory tubercle, without any progression in non-olfactory cortical areas .
Post-mortem studies investigating neuroinflammation in PD patients' brains have focused on midbrain structures. More extensive studies reported activated microglia also in the hippocampus and the temporal and entorhinal cortices . Despite the involvement of olfactory regions in PD and the importance of neuroinflammation in PD, only one study has focused on the OB and demonstrated microgliosis in the OB of PD patients . Due to its proximity to the olfactory epithelium and connections with the periphery, the olfactory system is very sensitive to exogenous pathogens, which might trigger local inflammation.
Sensibility of the Olfactory Epithelium and Olfactory Bulb to Inflammation
The olfactory epithelium is the first point of contact with the external environment. Mucocillaries of the olfactory epithelium act as a partial barrier against exogenous particles in the air [102, 103], but do not provide complete protection (for review see ). In humans, the thickness of the olfactory epithelium declines during aging  and thereby it might also become more permeable to particles and pathogens, increasing the risk of brain infections.
The organization of the human and rodent olfactory systems is similar  despite olfactory functions being less well developed in humans. In both species, the olfactory epithelium neurons, in contact with the external environment, project their axons into the glomerular layer of the OB, where they contact mitral cells, the relay cells of olfactory information. In rodents, these two types of cells have been shown to constitute a route for pathogen entry into the brain .
Further, in rodents, the OB contains a very dense population of microglial cells compared to other structures [107, 108], especially in the glomerular layer. A possible role of microglia in the OB is to phagocytose cellular debris  resulting from the high turnover of olfactory receptor neurons in the olfactory epithelium. Moreover, the microglia may also phagocytose OB interneurons  which are replaced throughout life in rodents, as well as possibly in humans, by adult neurogenesis [111, 112, 113]. Finally, OB microglia might also function as a sensor and barrier to exogenous particles and pathogens and could be involved in modulation and potentiation of neuroinflammation and associated disease [114, 115].
Among exogenous particles that can enter the OB, toxins (for review, see ), viruses, and particles (ultra-thin particles <100 nm, nanoparticles and microparticles) [99, 115, 117, 118, 119, 120, 121] have been widely studied. Studies in animal models have demonstrated that pathogens can be either blocked in the glomerular layer of the OB or spread though the axons of mitral cells to higher olfactory structures, such as the olfactory tubercle, amygdala, and olfactory cortex [114, 115].
Viruses Causing Inflammation in Olfactory Structures
The idea of a viral origin of PD was initially based on the observation that people born during the influenza pandemic 1918–1919 exhibit increased risk of developing parkinsonism, or so called post-encephalitic PD . Viral infections during childhood have also been generally associated with higher likelihood of developing PD . Moreover, diseases like asthma and seasonal and allergic rhinitis might be associated with PD , suggesting that chronic rhinitis, i.e., rhinitis-related inflammation, might promote the entry of neurotropic pathogens via the olfactory route . Interestingly, influenza A virus has been detected in the SNpc of PD brains , and the interferon-induced protein MxA, which plays a role in defense against influenza virus, is associated with LBs .
The infection by neurotropic viruses through the olfactory route has been widely studied in experimental animals. Rodent studies demonstrate that various types of viruses entering via the olfactory epithelium can infect different cell types in the OB, leading to dysfunction in olfactory circuits, and to the activation of glial cells located in the outer layers of the OB [114, 117, 119, 127, 128, 129, 130, 131]. Depending on the viral dose , an immune reaction involving type I interferons (e.g., IFN-α and IFN-β) can sometimes block the propagation of the virus from the OB to other brain regions , but the immune reaction can also induce widespread inflammation. The effects of influenza virus infection on olfactory regions have been well described in rodents [117, 128, 133]. Shortly after infusion of a mouse-adapted human influenza virus in the nasal cavity of mice, the viral antigen is found in the OB (and more precisely in glial cells), but not in other brain regions. Production of cytokines, such as IL-1β and TNF-α, increased considerably at the onset of disease. The neuronal release of TNF-α and IL-1β was also increased in other brain regions, including those directly connected with the OB (piriform cortex, olfactory tubercle, central amygdala) and others, such as the hypothalamus. Hence, local infection in the OB can induce inflammatory signals in distant brain regions and can trigger global neuroinflammation.
As mentioned above, activated microglia can phagocytose pathogens and unwanted cells  acquire an antigen-presenting cell phenotype and contribute to the recruitment of T cells . ROS and cytokines produced by microglia disrupt the blood brain barrier (BBB) [136, 137], and the effect of these inflammatory mediators is more pronounced in the olfactory epithelium and OB where the BBB already is more permeable than the BBB of other structures [138, 139, 140, 141]. Recently, the effect of TNF-α on BBB permeability was shown to favor CNS infection by the West Nile virus in mice . Thus, neuroinflammation in the OB might increase BBB permeability, facilitating the penetration of exogenous pathogens and triggering microgliosis and leukocyte invasion into the OB, sparking off a vicious circle of inflammation. Possibly, a similar mechanism plays a role in humans, after a neurotropic virus infection entering through the nose.
Recently, Jang and colleagues  studied the consequences of H5N1 viral infection in C57Bl/6 mice by intranasal inoculation. The H5N1 avian influenza virus spread from the periphery to the CNS (via cranial nerves) and was found in neurons and astrocytes in the solitary nucleus, locus coeruleus, and in periglomerular and mitral cells of the OB. Twenty-one days post inoculation, the virus was no longer found in the brain, but the immune response persisted at least 2 months. Importantly, this study was the first to demonstrate the effect of viral infection on α-syn aggregation. An increase in cellular and secreted phosphorylated α-syn (pSer129) was observed in the OB, locus coeruleus, hippocampus, and brainstem. Moreover, aggregated α-syn was found in the hippocampus, cortex, and brainstem along with a loss of dopaminergic neurons in SNpc . Taken together, these data point to the possibility that viral infection, maybe through inflammatory processes, can increase α-syn phosphorylation and induce/increase aggregation of α-syn in the brain.
Micro- and Nanoparticles Trigger Oxidative Stress and Inflammation in the OB
Certain metal particles might also be involved in PD, for example, LBs in the brain of PD patients have a high content of aluminum , or an enhanced risk to develop PD has been reported for subjects on a diet containing high quantities of iron . Several studies have demonstrated that various types of particles (gold, 13C, manganese oxide, titanium dioxide, ferric oxide) can be inhaled, deposited on olfactory epithelium, tracheobronchial epithelium, and in lung alveoli in humans and mice (for review, see [121, 146]). Some particles then reach the CNS through olfactory epithelium and OB [120, 147, 148, 149, 150, 151] and may trigger inflammatory processes in the olfactory circuits. For example, in mice, an intranasal administration of Fe2O3 induces microglial proliferation, activation, and recruitment in the OB. In vitro, exposure to Fe2O3 leads to the release of ROS and NO by a microglia cell line that at the same time increases their proliferation . Thus, chronic exposure to air particles, particularly in a polluted environment, could induce a chronic state of inflammation in olfactory and brain structures (for an extensive review on the involvement of viruses, particles, and pesticides in PD, see ).
Inflammation Process in the Olfactory Bulb: Local Consequences
Peripheral injection of lipopolysaccharide (LPS) is a widely used, but not very well understood, method to induce distant immune reactions in the rodent brain. Mori et al. and Ota et al. focused on olfactory regions and showed in mice a significant loss of cells in the OB and an increase in TNF-α and IκBα expression after peripheral LPS injection [153, 154]. Additionally, LPS administration increased expression of TNF receptors 1 and 2, and caspase 8 gene , as well as enhanced Fas expression . Two other studies showed that TNF-α itself has deleterious effects on olfactory cells, causing dysfunction of olfactory neurons  and inhibiting regeneration of olfactory mucosa . Moreover, when local inflammation in the OB after nasal instillation of a mycotoxin is coupled to a peripheral LPS injection, the expression of immune-stimulating genes is dramatically increased in the olfactory mucosa and the OB. This suggests that the effects of peripheral LPS could magnify apoptosis and inflammation in the olfactory epithelium and OB .
Neuroinflammation May Promote Progression of Synucleinopathy from the Gastrointestinal Tract to the CNS
In order to model some of the putative mechanisms in vivo and to validate clinical observations, appropriate rodent models reflecting the symptoms found in possible early stage diagnosed PD were studied . Some transgenic mice expressing mutant human α-syn encoded on artificial chromosomes reveal early aggregates of α-syn in the ENS and display motor deficits prior to detectable pathology in the CNS [172, 173]. In rats, intragastric injection of a selective proteasome inhibitor induced α-syn aggregation in DMV . In other studies, chronic intragastric administration of the mitochondrial toxin rotenone to rats was reported to induce a progressive accumulation of endogenous α-syn starting in the ENS and reaching the brain along the vagal and spinal cord nerve connections to the substantia nigra . Neuropathological changes in the toxicity-induced PD rat models were accompanied by local neuroinflammation. It can be assumed that the resulting tissue destruction and rotenone directly triggered a local immune activation and together this may have propagated the pathology from the GI system to the brain.
In support of a direct link between PD and gut immune status, it was found that the gene LRRK2, which is the major genetic cause for familial PD [176, 177, 178, 179, 180], is also located in a risk region for Crohn’s disease , an autoimmune-mediated chronic inflammatory bowel disease. In the brain, neuronal overexpression of LRRK2 accelerated the development of neuropathology in A53T α-syn transgenic mice, whereas its ablation suppresses neuronal aggregation and cytotoxicity of α-syn . In the peripheral immune system, LRRK2 is upregulated in macrophages under inflammatory conditions which promotes the production of ROS, phagocytosis, and killing of bacteria . The link between genetic risk for PD and GI immune mechanisms for LRRK2 is intriguing and warrants further studies to identify possible associations with progression of α-syn aggregation from the ENS to the brain.
Before doing so, a better understanding of the GI immune system is required. The intestines, and in particular the subepithelial lamina propria, contain the largest pool of tissue macrophages in humans. Thereby, the intestines share physiological similarities with the immune system of the olfactory epithelium. Macrophages in both locations demonstrate a two-edged sword: on one hand, they maintain tissue homeostasis by active phagocytosis of invading pathogens (e.g., bacteria, viruses) in the absence of excessive activation of other immune pathways [108, 166, 184]; on the other hand, they bear the potential to release an arsenal of detrimental cytokines, chemokines, and ROS [179, 180]. Thus, depending on the circumstances, GI macrophages have the potential to harm the surrounding tissue and may play a role in promoting the accumulation of α-syn in enteric nerves, leading to altered gut motility and constipation and, in later stages, to propagation of the pathology to the brain. If this indeed constitutes an etiological trigger in PD, then it could be relevant for developing earlier treatments and diagnosis of the disease.
Mechanisms of Cell-to-Cell Transfer
Conclusions and Proposed Hypothesis
Although α-syn aggregation appears to be central to the development and progression of PD pathology, inflammation also plays an important role in this disease. Immune activation in the GI tract or in the olfactory system via chemical or virus exposure might trigger α-syn misfolding, subsequent aggregation, and propagation to the brain. It is also possible that neuroinflammation promotes the prion-like transfer of α-syn by increasing its release, increasing its uptake, or both. However, further studies are needed to support this hypothesis. If correct, it will open up new avenues for early detection and therapeutic intervention. For example, one could speculate that it will be possible to develop therapies which slow down the progression of PD by reducing the underlying inflammation and mitigating its effects on cell-to-cell α-syn transfer. In addition, it is conceivable that it would be possible to adopt a preventive strategy and lower the risk of developing PD by treating the triggers of inflammation in the olfactory or gastrointestinal system.
This work was supported by a European Research Council Advanced Grant, Swedish Research Council, Human Frontier Science Program, the Parkinson Foundation in Sweden, and ERA-Net NEURON–MIPROTRAN to Patrik Brundin and a Roche Postdoctoral Fellowship to Stefan Grathwohl. Patrik Brundin is a member of BAGADILICO Linnaeus environment and MultiPark strategic research area at Lund University, both of which are sponsored by the Swedish Research Council.
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
- 7.Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045–2047PubMedCrossRefGoogle Scholar
- 9.Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173PubMedCrossRefGoogle Scholar
- 10.Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841PubMedCrossRefGoogle Scholar
- 11.Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67:1350–1356PubMedCrossRefGoogle Scholar
- 13.Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P (2011) alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121:715–725PubMedCrossRefGoogle Scholar
- 16.Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501–503PubMedCrossRefGoogle Scholar
- 17.Kurowska Z, Englund E, Widnerd H, Lindvalle O, Lia J-Y, Brundin P (2011) Signs of degeneration in 12–22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J Park Dis 1:83–92Google Scholar
- 28.Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182–192PubMedGoogle Scholar
- 34.Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J (2011) Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol 178:1509–1516PubMedCrossRefGoogle Scholar
- 48.Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752PubMedCrossRefGoogle Scholar
- 50.Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30:3184–3198PubMedCrossRefGoogle Scholar
- 64.Gundersen V (2010) Protein aggregation in Parkinson's disease. Acta Neurol Scand Suppl 190:82-87Google Scholar
- 65.Myohanen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, Garcia-Horsman JA, Baekelandt V, Mannisto PT, Lambeir AM (2012) A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol. doi: 10.1111/j.1476-5381.2012.01846.x
- 73.Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249(Suppl 3):III/1–5Google Scholar
- 87.Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenberger N, Thal DR, Kretzschmar H (2009) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635–652PubMedCrossRefGoogle Scholar
- 88.Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613–634PubMedCrossRefGoogle Scholar
- 92.Doty RL (ed) (2003) Handbook of olfaction and gustation. Marcel Dekker, New YorkGoogle Scholar
- 95.Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, N'Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, Galmiche JP, Damier P, Derkinderen P (2010) Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 5:e12728PubMedCrossRefGoogle Scholar
- 97.Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6:e28032PubMedCrossRefGoogle Scholar
- 101.Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV, Van Dam AM (2007) Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 42:762–771PubMedCrossRefGoogle Scholar
- 127.El-Habashi N, El-Nahass el S, Fukushi H, Hibi D, Sakai H, Sasseville V, Yanai T (2010) Experimental intranasal infection of equine herpesvirus 9 (EHV-9) in suckling hamsters: kinetics of viral transmission and inflammation in the nasal cavity and brain. J Neurovirol 16:242–248PubMedCrossRefGoogle Scholar
- 147.Calderon-Garciduenas L, Maronpot RR, Torres-Jardon R, Henriquez-Roldan C, Schoonhoven R, Acuna-Ayala H, Villarreal-Calderon A, Nakamura J, Fernando R, Reed W, Azzarelli B, Swenberg JA (2003) DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol Pathol 31:524–538PubMedCrossRefGoogle Scholar
- 163.Probst A, Bloch A, Tolnay M (2008) New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol: The Off J Eur Fed Neurol Soc 15(Suppl 1):1–4Google Scholar
- 167.Cersosimo MG, Benarroch EE (2011) Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis. doi: 10.1016/j.nbd.2011.10.014
- 171.Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH (2011) Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Dis: Off J Mov Dis Soc. doi: 10.1002/mds.23838
- 172.Greene JG (2011) Animal models of gastrointestinal problems in Parkinson's disease. J Park Dis 1:137–149Google Scholar
- 173.Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, Nussbaum RL (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 19:1633–1650PubMedCrossRefGoogle Scholar
- 176.Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595–600PubMedCrossRefGoogle Scholar
- 177.Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607PubMedCrossRefGoogle Scholar
- 181.Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40:955–962PubMedCrossRefGoogle Scholar
- 182.Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64:807–827PubMedCrossRefGoogle Scholar
- 188.Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, Baron T (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2011.06.022
- 190.Dunning CJ, Reyes JF, Steiner JA, Brundin P (2012) Can Parkinson's disease pathology be propagated from one neuron to another? Prog Neurobiol. doi: 10.1016/j.pneurobio.2011.11.003
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.